These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27520727)

  • 21. Tailoring of physicochemical properties of nanocarriers for effective anti-cancer applications.
    Chakraborty S; Dhakshinamurthy GS; Misra SK
    J Biomed Mater Res A; 2017 Oct; 105(10):2906-2928. PubMed ID: 28643475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
    Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bypassing multidrug resistant ovarian cancer using ultrasound responsive doxorubicin/curcumin co-deliver alginate nanodroplets.
    Baghbani F; Moztarzadeh F
    Colloids Surf B Biointerfaces; 2017 May; 153():132-140. PubMed ID: 28235723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymers help guide cancer drugs to tumor targets--and keep them there.
    Reynolds T
    J Natl Cancer Inst; 1995 Nov; 87(21):1582-4. PubMed ID: 7563199
    [No Abstract]   [Full Text] [Related]  

  • 26. Thymine-Modified Nanocarrier for Doxorubicin Delivery in Glioblastoma Cells.
    Ziganshina AY; Mansurova EE; Voloshina AD; Lyubina AP; Amerhanova SK; Shulaeva MM; Nizameev IR; Kadirov MK; Bakhtiozina LR; Semenov VE; Antipin IS
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment.
    Oliveira MS; Goulart GCA; Ferreira LAM; Carneiro G
    Expert Opin Drug Deliv; 2017 Aug; 14(8):983-995. PubMed ID: 27892713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The benefits and challenges associated with the use of drug delivery systems in cancer therapy.
    Cukierman E; Khan DR
    Biochem Pharmacol; 2010 Sep; 80(5):762-70. PubMed ID: 20417189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade.
    Sohail M; Guo W; Li Z; Xu H; Zhao F; Chen D; Fu F
    Curr Med Chem; 2021; 28(19):3753-3772. PubMed ID: 33019919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
    Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
    Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications.
    Ryu JS; Raucher D
    Expert Opin Drug Deliv; 2015 Apr; 12(4):653-67. PubMed ID: 25350837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation, Quality Control and Safety Issues of Nanocarriers Used for Cancer Treatment.
    Bianco ID; Ceballos MR; Casado C; Dabbene VG; Rizzi C; Mizutamari RK
    Curr Pharm Des; 2017; 23(35):5413-5425. PubMed ID: 28911309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro and Ex Vivo Permeability Studies of Paclitaxel and Doxorubicin From Drug-Eluting Biodegradable Ureteral Stents.
    Barros AA; Oliveira C; Reis RL; Lima E; Duarte ARC
    J Pharm Sci; 2017 Jun; 106(6):1466-1474. PubMed ID: 28257819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers.
    Ishida T; Kiwada H
    Biol Pharm Bull; 2013; 36(5):692-7. PubMed ID: 23649327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy].
    Chen WG; Wang SB
    Yao Xue Xue Bao; 2013 Jul; 48(7):1091-8. PubMed ID: 24133974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-targeting and pH-sensitive lipoprotein-mimic nanocarrier for targeted intracellular delivery of paclitaxel.
    Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Guo X; Chen D
    Int J Pharm; 2015 Mar; 480(1-2):116-27. PubMed ID: 25615984
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Folic Acid and Trastuzumab Functionalized Redox Responsive Polymersomes for Intracellular Doxorubicin Delivery in Breast Cancer.
    Lale SV; Kumar A; Prasad S; Bharti AC; Koul V
    Biomacromolecules; 2015 Jun; 16(6):1736-52. PubMed ID: 25918899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model.
    Al Faraj A; Shaik AS; Ratemi E; Halwani R
    J Control Release; 2016 Mar; 225():240-51. PubMed ID: 26827662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.